NAD+ and NMN are sold for the same promise — raising the body's level of a coenzyme that falls with age — and the search volume for "NAD vs NMN" reflects a buyer choosing between a drip and a capsule. Neither is a peptide; both are sold through the same channels as research peptides, which is why they are catalogued here. This page lays the two records side by side. It does not pick one.
What each molecule is
| NAD+ | NMN | |
|---|---|---|
| Full name | Nicotinamide adenine dinucleotide | Nicotinamide mononucleotide |
| Formula / molecular weight | C21H27N7O14P2 / 663.4 | C11H15N2O8P / 334.2 |
| Role | The coenzyme itself: carries electrons in energy metabolism, and is consumed by repair and signalling enzymes (sirtuins, PARPs) | A precursor, converted to NAD+ inside cells in one enzymatic step |
| How it is sold | Intravenous drips, intramuscular and subcutaneous injections | Capsules, powders and sublingual tablets |
| US regulatory status | No FDA-approved injectable label; compounded or sold as a research product | Dietary supplement (FDA response letter posted 29 September 2025) |
The size difference matters. NAD+ is a large, charged molecule, and the one published infusion study found infused NAD+ was "rapidly and completely removed from the plasma" before levels rose — the detail is on our NAD+ dosage page. NMN is about half its size and is taken by mouth, which is why the two products end up on different routes.
The human trial records, side by side
NMN — oral, small, short. ClinicalTrials.gov listed 32 studies with nicotinamide mononucleotide as an intervention on 30 September 2026, only one with posted results. The trials cited most often:
- Yoshino et al., Science 2021 (NCT03151239): 25 postmenopausal women with prediabetes and overweight, 13 on NMN 250 mg a day and 12 on placebo, 10 weeks. Muscle insulin sensitivity and insulin signalling rose on NMN and not on placebo. Two authors hold NMN-related patent interests, disclosed in the paper. It remains the only placebo-controlled women-only trial of an NAD+ precursor; the rest of the record for women, including unreported fertility trials, is on NAD for women.
- Yi et al., GeroScience 2023 (NCT04823260): 80 healthy middle-aged adults, placebo or 300, 600 or 900 mg a day, 60 days. Blood NAD rose in every NMN group; walking distance on a six-minute test improved; insulin resistance did not change; "no safety issues" were found. The lead author was employed by an NMN manufacturer.
- Christen et al., Nature Metabolism 2026 (NCT05517122): 65 adults, 14 days, comparing NMN, nicotinamide riboside and nicotinamide. NMN and nicotinamide riboside raised circulating NAD+ comparably; nicotinamide did not. The authors, from Nestlé Research, propose that gut bacteria convert NMN and nicotinamide riboside to nicotinic acid, which then drives the rise — meaning the capsule may work partly by a route other than intact NMN entering cells.
Every randomised NMN trial PubMed indexes, one row each. A PubMed search on 5 October 2026 for "nicotinamide mononucleotide" in the title, limited to randomised controlled trials, returned 13 records; the table carries the 11 that report an oral NMN arm with a dose (the other two are a post-hoc analysis of Yi 2023 and a trial whose abstract gives no NMN dose).
| Trial | People | Daily NMN | Length | Blood NAD+ | Main reported result | Who ran or funded it |
|---|---|---|---|---|---|---|
| Yoshino, Science 2021 | 25 women with prediabetes | 250 mg | 10 weeks | Not reported in abstract | Muscle insulin sensitivity rose | Two authors hold NMN patent interests |
| Liao, JISSN 2021 | 48 amateur runners | 300, 600 or 1,200 mg | 6 weeks | Not reported in abstract | Aerobic measures rose more at 600 and 1,200 mg; VO2max itself unchanged | University and institute authors only |
| Kim, Nutrients 2022 | 108 older adults | 250 mg (morning or afternoon) | 12 weeks | Not reported in abstract | Sit-to-stand and drowsiness improved most in the afternoon group | Co-authors from Mitsubishi Corporation Life Sciences |
| Fukamizu, Sci Rep 2022 | 31 healthy adults, 20–65 | 1,250 mg | 4 weeks | Safety study | No changes beyond normal variation; no severe adverse events | Funded by Mitsubishi Corporation Life Sciences |
| Pencina, J Gerontol A 2023 | 32 adults, 55–80, overweight | 1,000 mg once or twice | 14 days | Dose-related rise | Blood NMN 1.7× and 3.7× baseline; adverse events similar to placebo | Co-authors from the formulation's maker |
| Akasaka, Geriatr Gerontol Int 2023 | 14 men ≥65 with diabetes | 250 mg | 24 weeks | Not reported in abstract | Grip strength and walking speed: no difference | Co-authors from Teijin and NOMON Co. |
| Yi, GeroScience 2023 | 80 healthy middle-aged adults | 300, 600 or 900 mg | 60 days | Rose in every NMN group | Six-minute walk improved; insulin resistance unchanged | Lead author employed by an NMN maker |
| Katayoshi, Sci Rep 2023 | 36 healthy middle-aged adults | 125 mg twice | 12 weeks | Serum nicotinamide higher | Arterial stiffness: no significant difference | Run by DHC Corporation's laboratories |
| Morifuji, GeroScience 2024 | 60 older adults | 250 mg | 12 weeks | Rose | Primary stepping test: no difference; 4-metre walk faster, sleep scores better | Run by Meiji's laboratories |
| Christen, Nat Metab 2026 | 65 adults | NMN vs NR vs nicotinamide | 14 days | Rose, comparable to NR | Rise may run through gut bacteria | Nestlé Research |
| Shiraki, Geriatr Gerontol Int 2026 | 14 men (28 eyes) ≥65 with diabetes | 250 mg | 24 weeks | — | Retinal thickness change differed (p = 0.006); same team and design as Akasaka 2023 | Co-authors from Teijin and NOMON Co. |
Read across the rows, the pattern is consistent: oral NMN raises NAD+ or its metabolites in blood, and the functional results are mixed — several primary outcomes did not move, and most positive findings are secondary measures in trials of 14 to 108 people. Ten of the eleven list a company author or company funding; Liao 2021 is the exception.
NAD+ — injected, fewer and more varied. The human injection record runs from 5 mg to roughly 700 mg per session, in a handful of studies:
- Yu et al., American Journal of Cardiovascular Drugs 2026: 180 adults with heart failure from ischaemic cardiomyopathy, NAD+ 10 mg intravenously once a day for 7 days, or placebo, alongside standard treatment. Ejection fraction at one month was 45.44% against 42.44% (p = 0.024); hospitalisation and symptom-class differences were not statistically significant. This is the largest randomized placebo-controlled NAD+ injection trial we have located.
- The wellness doses are on another scale. A US trial registration and a research vendor's vial both use 500 mg, fifty times the heart-failure trial's daily dose; our NAD+ dosage page traces the fifty-fold gap between the trial and clinic doses. Which of the two routes has been shown to raise NAD+ in people is on our NAD+ injection vs oral page.
The two have never been compared in a trial. We found no registered or published study that randomised people to injected NAD+ versus oral NMN. Any "which is better" answer is an inference across different routes, doses, populations and outcomes. Glutathione presents the same injected-versus-swallowed question with the same missing trial, laid out on our glutathione injection vs oral page.
Side effects, as recorded
- Injected NAD+. A 2026 retrospective review of a wellness clinic's records found every client given 500 mg intravenously on four consecutive days reported cramping, nausea or other symptoms, and infusions were slowed as a result. FDA's January 2026 warning letter to a compounding facility records three patients sent to the emergency room with low blood pressure and uncontrollable shaking after NAD+ from one lot that contained bacterial endotoxins. The full record, with FAERS counts, is on our NAD+ injection side-effects page.
- Oral NMN. The published trials — up to 1,250 mg a day for four weeks (Fukamizu 2022), 2,000 mg a day for 14 days (Pencina 2023) and 250 mg a day for 24 weeks (Akasaka 2023) — report no safety signal. They are small, short, in healthy or prediabetic adults, and several are funded or staffed by manufacturers. FDA's adverse-event database held 8 reports naming "NMN" and 5 naming "nicotinamide mononucleotide" on 30 September 2026 — low numbers that reflect how rarely supplement users report, not measured safety. The other oral precursors — nicotinamide riboside, nicotinamide and niacin — have their own records, set side by side on our oral NAD+ precursor side-effects page. How NMN stands against nicotinamide riboside specifically is on the two precursors compared head to head.
Where the records do not reach
- Any head-to-head comparison of NAD+ and NMN.
- Whether raising blood NAD+ by either route changes any hard health outcome in people.
- Long-term use: the longest NMN trials we found ran 24 weeks, in 14 older men with diabetes (two papers from one team); no NAD+ injection trial ran beyond weeks.
- Whether a given NMN capsule contains what its label says — supplement makers are not required to prove content to FDA before sale — or a given NAD+ vial is sterile and endotoxin-free, which the GenoGenix letter shows cannot be assumed.
Anyone weighing either for a medical reason should bring the specific product and this record to a doctor. The related compound often stacked with both, glutathione, has its own dosage page.
Sources and dates
- PubChem CID 14180 (NMN) and CID 5892 (NAD+), computed properties, read 2026-09-30.
- Regulations.gov docket FDA-2023-P-0872, document FDA-2023-P-0872-2754, "Response Letter from FDA HFP to Natural Products Association and Alliance for Natural Health USA", posted 2025-09-29 (document record read through the regulations.gov API 2026-09-30; the letter's PDF was not retrievable from here, and its conclusion is as summarised by the petitioner, Natural Products Association, in its release of the same date).
- Yoshino M et al. Science 2021;372(6547):1224-1229 (PMID 33888596; full text PMC8550608, methods read; registry NCT03151239).
- Yi L et al. GeroScience 2023;45(1):29-43 (PMID 36482258; NCT04823260).
- Christen S et al. Nat Metab 2026;8(1):62-73 (PMID 41540253; NCT05517122).
- PubMed search, "nicotinamide mononucleotide"[ti] AND randomized controlled trial[pt], 13 records, 5 October 2026; abstracts read: Liao 2021 (PMID 34238308), Kim 2022 (35215405), Fukamizu 2022 (36002548), Pencina 2023 (35182418), Akasaka 2023 (36443648), Katayoshi 2023 (36797393), Morifuji 2024 (38789831), Shiraki 2026 (42082179).
- Yu X et al. Am J Cardiovasc Drugs 2026;26(1):97-106 (PMID 40954388).
- ClinicalTrials.gov v2 API, intervention "nicotinamide mononucleotide": 32 studies, 1 with results (NCT04571008), 2026-09-30. openFDA drug adverse-event endpoint, medicinal product "NMN" (8) and "NICOTINAMIDE MONONUCLEOTIDE" (5), 2026-09-30.
- Our NAD+ dosage page (read 2026-09-17 sources) and NAD+ injection side-effects page (FAERS count 2026-09-25) for the NAD+ injection figures carried here.
Corrections go to the contact page.
